Cancers · 2023 · 10 citations · 53 references
MedicineCancer BiologyOncologyMolecular OncologyNeuro-oncologyTumor MicroenvironmentAngiogenesisAngiogenesis In CancerBrain TumorsCancer BiomarkersGlioblastomaTumor MarkersBiomarkersGlioblastoma BiomarkersGlioblastoma PrognosisGlioblastoma Tumor MicroenvironmentPatient Outcome EvaluationPatient Outcome PredictionTemozolomide TherapyTumor Microenvironment Biomarkers
Glioblastoma (GB) is one of the deadliest human cancers. Many GB patients do not respond to treatment, and inevitably die within a median of 15-18 months post-diagnosis, highlighting the need for reliable biomarkers to aid clinical management and treatment evaluation. The GB microenvironment holds tremendous potential as a source of biomarkers; several proteins such as MMP-2, MMP-9, YKL40, and VEGFA have been identified as being differentially expressed in GB patient samples. Still to date, none of these proteins have been translated into relevant clinical biomarkers. This study evaluated the expression of MMP-2, MMP-9, YKL40, and VEGFA in a series of GBs and their impact on patient outcome. High levels of VEGFA expression were significantly associated with improved progression-free survival after bevacizumab treatment, thus having potential as a tissue biomarker for predicting patients' response to bevacizumab. Noteworthily, VEGFA expression was not associated with patient outcome after temozolomide treatment. To a lesser extent, YKL40 also provided significant information regarding the extent of bevacizumab treatment. This study highlights the importance of studying secretome-associated proteins as GB biomarkers and identifies VEGFA as a promising marker for predicting response to bevacizumab.
53
Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Roger Stupp, Warren Mason, Martin J. van den Bent et al. · New England Journal of Medicine · 2005 · 21.6K citations · Full text
A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
Mark R. Gilbert, James J. Dignam, Terri S. Armstrong et al. · New England Journal of Medicine · 2014 · 2.8K citations · Full text
Medicine, Oncology, Pharmacotherapy +17
Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma
Olivier Chinot, Wolfgang Wick, Warren Mason et al. · New England Journal of Medicine · 2014 · 2.5K citations · Full text
Medicine, Oncology, Pharmacotherapy +15
Karl H. Plate, Georg Breier, Herbert A. Weich et al. · Nature · 1992 · 2.3K citations
Medicine, Cancer Biology, Oncology +16
VEGF Inhibits Tumor Cell Invasion and Mesenchymal Transition through a MET/VEGFR2 Complex
Kan Lu, Jeffrey P. Chang, Christine A. Parachoniak et al. · Cancer Cell · 2012 · 555 citations · Full text
Medicine, Cancer Biology, Oncology +16